Abstract: Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) ?-polyglutamic acid (?-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the ?-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising ?-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient.

Abstract: The present invention is related to a kit comprising: (a) a mesenchymal stem cell; (b) a gelatin-hyaluronan-chondroitin tri-copolymer scaffold; (c) a kartogenin; and (d) a bioreactor. The present invention is also related to a method for promoting differentiation of a mesenchymal stem cell into cartilage tissue, comprising: (a) culturing the mesenchymal stem cell on a gelatin- hyaluronan-chondroitin tri-copolymer scaffold in the presence of a kartogenin; and (b) culturing the mesenchymal stem cell and the gelatin-hyaluronan-chondroitin tri-copolymer scaffold in a bioreactor.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: A corneal cover or corneal implant to be placed within or onto the surface of the cornea is made of bony fish scales and a contact lens is made of bony fish scales.

Abstract: A non-alcohol mouthwash composition without chemical antibacterial medicament is disclosed. The non-alcohol mouthwash composition includes from 0.03% to 1.5% of ?-polyglutamic acid (?-PGA) and from 0.5% to 4% of surfactant, all percentages based on the total weight of the mouthwash composition. The non-alcohol mouthwash composition preferably includes from 0.4% to 1.5% by weight, or more preferably from 0.8% to 1.3% by weight, of ?-PGA. Containing no chemical antibacterial medicament, the non-alcohol mouthwash composition can effectively inhibit bacterial growth in the oral cavity without irritating the oral mucosa.

Abstract: The present invention relates to a method for manufacturing a triple cross-linked collagen, which comprises the following steps: providing a soluble collagen sample; mixing the collagen sample with a first cross-linking agent to form a one cross-linked collagen; mixing the first cross-linked collagen with a second cross-linking agent to form a second cross-linked collagen; and mixing the second cross-linked collagen with a third cross-linking agent to form a triple cross-linked collagen, wherein each of the first cross-linking agent, the second cross-linking agent, and the third cross-linking agent is selected from the group consisting of an aldehyde cross-linking agent, an imine cross-linking agent, and an epoxide cross-linking agent. In addition, the first cross-linking agent is different form the second cross-linking agent, and the third cross-linking agent is different form the first cross-linking agent and the second cross-linking agent.

Abstract: A non-alcohol mouthwash composition without chemical antibacterial medicament is disclosed. The non-alcohol mouthwash composition includes from 0.03% to 1.5% of ?-polyglutamic acid (?-PGA) and from 0.5% to 4% of surfactant, all percentages based on the total weight of the mouthwash composition. The non-alcohol mouthwash composition preferably includes from 0.4% to 1.5% by weight, or more preferably from 0.8% to 1.3% by weight, of ?-PGA. Containing no chemical antibacterial medicament, the non-alcohol mouthwash composition can effectively inhibit bacterial growth in the oral cavity without irritating the oral mucosa.

Abstract: The present invention discloses a desensitizing toothpaste. Based on the total weight of the desensitizing toothpaste, the desensitizing toothpaste includes: from 5% to 40% by weight of DP-bioglass; from 1% to 5% by weight of thickening agents; from 25% to 35% by weight of humectant; and from 1% to 5% by weight of surfactant, wherein the DP-bioglass includes: 8.4% of Na2O, 40.6% of CaO, 39% of SiO2, and 12% of P2O5 based on the total weight of the DP-bioglass. With the implementation of the present invention, the indication of dentin hypersensitivity can be greatly relieved.

Abstract: A detection method for cancer is provided. Magnetic carbon beads are used. The carbon beads are highly specified to a cancer. Surface area of grafted antigen are broadened by grafting functional molecules. Number of antigen is increased on the surface. Thus, the present invention improves sensitivity and accuracy of disease detection and greatly saves cost. The present invention can be applied for sample purification or massive disease detection.

Abstract: A method is provided for modifying a radioactive carbon nanotube (CNT) carrier. Magnetic molecules are used. The modified CNT is highly specified to disease. Surface of the CNT has functional grafts for catching antigen/antibody. Antigen/antibody thus caught on the surface is increased in number. Thus, the present invention improves sensitivity and accuracy of disease detection and greatly saves cost. The present invention can be applied for sample purification or massive disease detection.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: The present invention provides a kit comprising a cell transfected with hepatic transcription regulators, and a culture medium that support growth of the cell. The present invention further provides a method for determining drug metabolism and predicting drug toxicity, comprising transfecting a cell with hepatic transcription regulators, and culturing the cell on a medium.

Abstract: A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.

Abstract: A method of preparing magnetic bead type nasopharyngeal enzyme immunoassay reagents by polymerase chain reaction according to this invention offers in-vitro diagnostic reagents by means of utilizing nanotechnology. This method uses magnetic beads to coat EBV nuclear antigen (Epstein-Barr virus nuclear antigen, EBNA1) or early antigen (Early Antigen, EA). The use of polymerase chain reaction (polymerase Chain Reaction PCR) is for amplified detection. It is found that positive controls of different concentrations, after amplified by PCR, change in their brightness and concentration. That reveals the EBV antigens on the magnetic beads can specifically detect IgA antigens in the serum.

Abstract: An implant containing a collagen matrix embedded with chondrocyte-like cells, its use in repairing a chondral defect, and a method of preparing the implant.

Abstract: Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) ?-polyglutamic acid (?-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the ?-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising ?-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient.

Abstract: Methods and compositions for producing a cellular drug release are disclosed. The method comprises: a) providing a composition comprising a therapeutically effective amount of a pharmacological agent adsorbed onto mesoporous hydroxyapatite (HAP) with hydrophobic surfaces; b) exposing the composition to a cell; c) causing entry of the mesoporous HAP into the cell and degradation of the HAP in the lysosomes of the cell and desorption of the agent from the mesoporous HAP; d) causing release of the desorbed agent from the lysosomes into the cytoplasm of the cell; and e) causing release of the desorbed agent to outside the cell. The composition comprises a) mesoporous HAP with hydrophobic surfaces; and b) a therapeutically effective amount of a pharmacological agent, adsorbed onto the hydrophobic surfaces of the mesoporous. HAP. The composition is characterized in that it constantly releases the agent in vivo for a period of at least 4 weeks.

Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a method for manufacturing a triple cross-linked collagen, which comprises the following steps: providing a soluble collagen sample; mixing the collagen sample with a first cross-linking agent to form a one cross-linked collagen; mixing the first cross-linked collagen with a second cross-linking agent to form a second cross-linked collagen; and mixing the second cross-linked collagen with a third cross-linking agent to form a triple cross-linked collagen, wherein each of the first cross-linking agent, the second cross-linking agent, and the third cross-linking agent is selected from the group consisting of an aldehyde cross-linking agent, an imine cross-linking agent, and an epoxide cross-linking agent. In addition, the first cross-linking agent is different form the second cross-linking agent, and the third cross-linking agent is different form the first cross-linking agent and the second cross-linking agent.

Abstract: A composition comprising a polymer that comprises oxidated hyaluronic acid cross-linked by a dihydrazide is disclosed. The polymer is a hydrogel exhibiting the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37° C. These characteristics make it useful as a vitreous humor substitute.